Digital Health
DiagnaMed Anticipates CERVAI Commercial Launch In Q4 2023
DiagnaMed Holdings (CSE: DMED) is expected to begin the deployment of its brain age estimation tool known as CERVAI to third party sites in the fourth…
FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.
DiagnaMed Holdings (CSE: DMED) is expected to begin the deployment of its brain age estimation tool known as CERVAI to third party sites in the fourth quarter of 2023.
“We are excited about the development progress we have made with CERVAI, our proprietary generative AI brain health platform, and we expect to have our initial commercial launch for clinic or at-home use in Q4-2023,” commented CEO Fabio Chianelli in an updated issued this morning by the company.
The tool, developed in combination with Drexel University under license, consists of an EEG headset that uses machine learning techniques and data recording protocols to evaluate overall brain health. The assessment tool generates both self-report and clinician-observed measures to output a patient risk score and provide actionable points for improvement. The tech incorporates the use of OpenAI’s ChatGPT to develop personalized treatment plans and interventions for mental health and neurodegenerative conditions.
READ: DiagnaMed Launches Dr. GenAI, A Generative AI Medical Chatbot
The first phase of the development of the tool is said to have been completed, which included laboratory-based testing of indiviudals. The model is said to have accurately predicated chronological ages with “a medium-to-strong statistical effect-size.” The final phase of development will now see the EEG headsets used at home by individuals to test the tech in various settings.
With commercialization expected to begin in the fourth quarter, the company intends to tackle the target markets of health and wellness clinics, fitness clubs, physician offices, and sports clubs among other targets.
“We expect CERVAI to be a practical tool for the millions of people with mental illness and neurodegenerative diseases,” continued Chianelli.
Diagnamed Holdings last traded at $0.075 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
The post DiagnaMed Anticipates CERVAI Commercial Launch In Q4 2023 appeared first on the deep dive.
Keep it Short
By KIM BELLARD OK, I admit it: I’m on Facebook. I still use Twitter – whoops, I mean X. I have an Instagram account but don’t think I’ve ever posted….
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….
Seattle startup Olamedi building platform to automate health clinic communications
A new Seattle startup led by co-founders with experience in health tech is aiming to automate communication processes for healthcare clinics with its software…
